Article Information
History
- August 28, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Kangyun Wu1,
- Yong Zhang1,
- Huiqing Yin-DeClue1,
- Kelly Sun1,
- Dailing Mao1,
- Erika C. Crouch2,
- Derek E. Byers1 and
- Michael J. Holtzman1,3,4,*
- 1Pulmonary and Critical Care Medicine, Department of Medicine, Washington University School of Medicine, St. Louis, MO, USA 63110
- 2Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA 63110
- 3Department of Cell Biology and Physiology, Washington University School of Medicine, St. Louis, MO, USA 63110
- 4NuPeak Therapeutics Inc., St. Louis, MO 63105
- ↵*Address correspondence to: Michael J. Holtzman, Washington University School of Medicine, 660 S. Euclid Avenue, St. Louis, MO 63110, mjholtzman{at}wustl.edu.
Posted August 28, 2024.
The post-viral GPNMB+ immune niche persists in long-term Covid, asthma, and COPD
